--- a
+++ b/clusters/9knumclustersv2/clust_1100.txt
@@ -0,0 +1,93 @@
+Patient should be human leukocyte antigen (HLA) typed (A, B, C, DR and DQ) during induction therapy phase or a written explanation for not undergoing HLA typing on the flow sheet
+Any human leukocyte antigen (HLA) type; (historic HLA typing is permitted)
+Human leukocyte antigen (HLA)-A, A, A, B, or B.
+No suitable human leukocyte antigen (HLA)-identical sibling donor
+DONOR: Human leukocyte antigen (HLA) haplo-identical matched related.
+Donor and recipient match each other for at least / human leukocyte antigen (HLA)-loci (HLA-A, B, C, and D-related [DR]).
+Lack human leukocyte antigen (HLA)-identical related donor
+Relapsed AML after human leukocyte antigen (HLA)-matched related or unrelated allogeneic hematopoietic cell transplant (per IWG definition of relapse)
+Availability of a CB unit matched with the patient at , , or / human leukocyte antigen (HLA) class I (serological) and II (molecular) antigens.
+Patients must have one related donor who is human leukocyte antigen (HLA) mismatched in the GVHD direction at two or more HLA loci
+Available human leukocyte antigen (HLA)-haploidentical donor that meets the criteria
+Human leukocyte antigen (HLA)-A* (HLA-A.) positivity by molecular subtyping
+Availability of appropriate, willing, human leukocyte antigen (HLA)-matched related stem cell donor
+No more than  antigen mismatch at human leukocyte antigen (HLA)-A, B, C, DRB and DQB locus for either related or unrelated donor
+Human leukocyte antigen (HLA)-A* (HLA-A.) positivity by molecular subtyping (blood test or buccal swab, historical documentation acceptable)
+Patients must be human leukocyte antigen (HLA)-A+
+Has a human leukocyte antigen (HLA)-matched or single allele-mismatched adult sibling serving as donor
+Human leukocyte antigen (HLA)-A positive based on flow cytometry
+DONOR: Human leukocyte antigen (HLA)-matched or  antigen mismatched sibling donor
+Human leukocyte antigen (HLA)-identical sibling or / matched unrelated donor transplant
+No available suitable human leukocyte antigen (HLA)-matched donor
+Absence anti-human leukocyte antigen (HLA) antibodies specific for HLA class I antigens expressed by the coagulation factor III (thromboplastin, tissue factor) (F).cytosine deaminase (CD).carboxylesterase (CE) NSCs
+Patients must be human leukocyte antigen (HLA)-DP positive
+/ human leukocyte antigen (HLA) matched family donor available
+Patients must be human leukocyte antigen (HLA)-A* positive
+Leukocyte >= ,/ul
+Patients must have a cord blood (CB) unit available which is matched with the patient at , , or / human leukocyte antigen (HLA) class I (serological) and II (molecular) antigens
+Human leukocyte antigen (HLA)-A* (HLA-A.) positivity by molecular subtyping
+Human leukocyte antigen (HLA)-A positive
+DONOR: Donor's high resolution human leukocyte antigen (HLA) typing must be available for review
+Patients must have a related donor who is human leukocyte antigen (HLA) mismatched at , , or  antigens at the HLA-A; B; C; DR loci in the GVHD direction; (patients with related donors who are HLA identical or are a -antigen mismatch may be treated on this therapeutic approach, but will have their outcomes will not be part of the statistical aims of the study)
+Patients must have a related donor who is either human leukocyte antigen (HLA)-identical or a one antigen mismatch at the HLA- A; B; C; and DR loci
+Allogeneic transplant with a human leukocyte antigen (HLA)-identical sibling will be recommended for patients <  years; if the patient refuses allogeneic transplant, they may still be eligible for this protocol
+The UCB graft is matched at - human leukocyte antigen (HLA)-A, B, DRB antigens with the recipient; this may include - antigen mismatches at the A or B or DRB loci
+Patient has at least one medically fit first- or second-degree family member expected to be human leukocyte antigen (HLA) mismatched at -/ loci; in addition, the prospective donor is willing to voluntarily donate hematopoietic stem cells and sign consent forms
+Patients must have a cord blood unit available which is matched with the patient at , , or / human leukocyte antigen (HLA) class I (serological) and II (molecular) antigens
+ENROLLMENT: Confirmation that a cord blood donor which is matched with the recipient at a , , or / human leukocyte antigen (HLA) class I (serological) and HLA class II (molecular) antigens.
+Availability of a suitable human leukocyte antigen (HLA)-matched related donor
+Patients must have human leukocyte antigen (HLA)-A phenotype
+Human leukocyte antigen (HLA)-A, -A, -A, or -A positive
+Any human leukocyte antigen (HLA) type
+Patient has anti-human leukocyte antigen (HLA) antibodies specific for HLA antigens expressed by the HB.F.CD NSCs
+Patients must express human leukocyte antigen (HLA) -A+, -A+, or -A+ (% of patients)
+DONOR: Human leukocyte antigen (HLA)-identical related donors or
+Patients will be tested for human leukocyte antigen A (HLA-A) as determined by flow cytometry followed by molecular analysis of a peripheral blood specimen; however this result will not be an inclusion criterion
+Consenting first degree relative matched at / human leukocyte antigen (HLA) antigens (A, B, and DR)
+Lack of a suitable human leukocyte antigen (HLA)-matched related donor
+DONOR: Human leukocyte antigen (HLA) identical to recipient subject
+Patients must have a cord blood (CB) unit available which is matched with the patient at , , , or / human leukocyte antigen (HLA) class I (serological) and II (molecular) antigens
+Human leukocyte antigen (HLA)-A* (HLA-A.) positivity by molecular subtyping
+Human leukocyte antigen (HLA)-A positive
+Expression of human leukocyte antigen (HLA)-A: or HLA-A:.
+ELIGIBILITY FOR TREATMENT ON ARM : Patients must express human leukocyte antigen (HLA)-A*
+Human leukocyte antigen (HLA)-A-positive
+Human leukocyte antigen HLA A positive
+Expression of human leukocyte antigen (HLA)-A
+Patients must have one related donor who is human leukocyte antigen (HLA) mismatched in the GVHD direction at two or more HLA loci
+Patients must NOT have a human leukocyte antigen (HLA)-matched sibling
+Has a suitable human leukocyte antigen (HLA) haploidentical donor available
+Patients must have undergone a human leukocyte antigen (HLA) matched (sibling) allogeneic HCT for a hematologic or lymphoid malignancy other than chronic myelogenous leukemia (CML) who have recurrent or persistent disease and are otherwise eligible for donor leukocyte infusions; CML patients with persistent disease after receiving donor lymphocyte infusion of at least  x ^ cells/kg will be eligible for CD+ memory T cell infusion
+A fully human leukocyte antigen (HLA) matched or single antigen/allele mismatched sibling or unrelated donor is available
+Human leukocyte antigen (HLA)-A positive by deoxyribonucleic acid (DNA) sequence analysis (by history or as part of this study); HLA testing can be done at local labs
+DONOR: Related or unrelated human leukocyte antigen (HLA) identical donors who are in good health and have no contra-indication to donation
+Donor is blood-related and human leukocyte antigen (HLA)-haploidentical to the recipient
+Patient must have a partially (>= / class I antigen) human leukocyte antigen (HLA)-matched (by serology or low resolution deoxyribonucleic acid [DNA] testing) relative able to serve as a donor
+DONOR: Donors will be selected to minimize human leukocyte antigen (HLA) mismatch in the host-versus-graft direction
+Patients must be human leukocyte antigen (HLA)-A* positive
+Available peptide-MHC pair that can be folded into a tetramer for which MCPyV TAg-specific cells can be generated and reactivity to cell lines expressing MCPyV TAg with the corresponding human leukocyte antigen (HLA)
+Human leukocyte antigen (HLA)-A*+ by serology by an ASHI accredited laboratory;
+Leukocyte count </L,
+Has a potentially suitable human leukocyte antigen (HLA) haploidentical donor available
+Patients must be human leukocyte antigen (HLA) A positive by polymerase chain reaction (PCR) typing
+Human leukocyte antigen (HLA) type A or A
+Patients must be human leukocyte antigen (HLA)-A*:-positive
+Human leukocyte antigen (HLA)-A positive.
+No more than  antigen mismatch at Human Leukocyte Antigen (HLA)-A, -B, -C, -DRB or -DQB locus for either related or unrelated donor; and
+Must have consenting sibling matched at / human leukocyte antigen (HLA) antigens (A, B, DR)
+Any human leukocyte antigen (HLA) type (historic HLA typing is permitted)
+Patients must be human leukocyte antigen (HLA)-A* positive
+Human leukocyte antigen (HLA)-A or HLA-A
+DONOR: Human leukocyte antigen (HLA) >= / related or unrelated donors
+Planned related HCT with molecular / (haploidentical) intermediate/high resolution human leukocyte antigen (HLA) donor allele matching
+Availability of a willing and suitable human leukocyte antigen (HLA) identical related donor
+Recipient of -/ human leukocyte antigen (HLA)-matched (HLA-A, -B, -C, -DRB) allogeneic hematopoietic stem cell transplantation
+Human leukocyte antigen (HLA)-identical sibling donor
+Patients transplanted from related or unrelated, human leukocyte antigen (HLA)-matched or mismatched donors
+Participants must be human leukocyte antigen (HLA)-A positive
+Presence of human leukocyte antigen (HLA) antibodies
+No available human leukocyte antigen (HLA)-matched related donor
+Availability of an human leukocyte antigen (HLA) matched related donor
+Human leukocyte antigen (HLA) mismatched related or unrelated donor identified / or /
+Availability of human leukocyte antigen (HLA)-identical sibling donor
+The patient has a human leukocyte antigen (HLA)-matched donor and is eligible for allogeneic transplantation for CML treatment.